Trials / Not Yet Recruiting
Not Yet RecruitingNCT06830395
Study of CM313 in Subject With IgA Nephropathy
A Phase II Clinical Study to Evaluate the Safety and Efficacy of CM313 (SC) Injection in Subjects With Primary IgA Nephropathy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK) characteristics, Pharmacokinetics(PD) effects, and immunogenicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM313 | CM313(SC) injection |
| DRUG | Placebo | Matched placebo |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2027-03-01
- Completion
- 2028-08-01
- First posted
- 2025-02-17
- Last updated
- 2025-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06830395. Inclusion in this directory is not an endorsement.